Mr. Joshua Bartch reports

MYDECINE INNOVATIONS GROUP ANNOUNCES CHANGES TO BOARD AND MANAGEMENT

Mydecine Innovations Group Inc. has appointed Peter Field to its board of directors, effective March 18, 2025. Mr. Field is a seasoned entrepreneur with over 30 years of experience in business development, product innovation, and leadership. Based in Vancouver, he has been involved in ventures leveraging advanced technologies, including an artificial-intelligence-driven vertical farming platform and pharmaceutical commercialization. He has helped build and manage two GMP (good manufacturing practice), USFDA-certified manufacturing facilities and has invested in biotech companies focused on wound care, Alzheimer's, depression and cancer biomarkers. More recently, as president of a biotech company, Mr. Field has as gained extensive experience in public markets, capital raises and regulatory compliance, playing a pivotal role in securing funding and guiding corporate governance.

In addition, the company has appointed Michael Callas to its board of directors, effective March 21, 2025, following the resignation of Robert Roscow.

Mr. Callas is the founder and chief executive officer of EVOOAI, a company dedicated to preserving human creativity in an AI-driven world. As the former chief strategy officer at Vacuumlabs, he played a key role in launching Daylight, highlighting his commitment to inclusivity in fintech (financial technology). He has also held leadership positions at EY and Vodafone, driving digital transformation and emerging technology initiatives. Beyond the tech industry, Mr. Callas has served as CEO of StepOne Ventures, fostering innovation and mentoring entrepreneurs, and as executive director of Jovenes con Futuro, connecting Spain's top young tech talent with startups in Silicon Valley and New York. An internationally acclaimed operatic baritone, he blends artistic and business expertise and holds an academic role at the Istituto Europeo di Design. Recognized as a "tech tastemaker" by Details Magazine, he continues to shape the tech industry through mentorship, education and creative vision.

The company also announces the resignation of Damon Michaels as its chief operating officer of the company, effective January 22, 2025.

The company extends its sincere appreciation to Mr. Roscow and Mr. Michaels for their valuable contributions and wishes them success in their future endeavours.

About Mydecine Innovations Group Inc.

Mydecine Innovations Group is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and posttraumatic stress disorder (PTSD). The core strategy blends advanced technology with an elaborate infrastructure for drug discovery and development. Mydecine's dedicated multinational team constantly develops new paths for breakthrough treatment solutions in areas with considerable unmet needs. By collaborating with some of the world's leading specialists, the company aspires to responsibly speed up the development of breakthrough medications to provide patients with safer and more effective treatment solutions. At the same time, Mydecine's approach focuses on the next generation of psychedelic medicine by creating innovative compounds with unmatched therapeutic potential through its clinical trial efforts with world-class scientific and regulatory expertise.

We seek Safe Harbor.